Sanofi (France) (SAN.PA) to Start China Clinical Trial of Cancer Drug In-licensed from Shanghai Institutes for Biological Sciences  
5/29/2012 9:19:32 AM

by Richard Daverman, PhD

May 25, 2012 -- Sanofi hopes to begin a Phase I clinical trial in China next year of a novel drug that targets liver cancer. The molecule inhibits the slit-robo signaling path that controls tumor vasculature and tumor growth, a discovery made by researchers at the Shanghai Institute of Biological Sciences (SIBS). Sanofi in-licensed global rights from SIBS to the molecule in 2010 for a reported $60 million upfront payment. More details....

Stock Symbol: (NYSE: SNY)